A Phase III, International, Multicenter, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Tolerability of Intravenous Antegren (Natalizumab) in Subjects with Moderately to Severely Active Crohn's Disease (AN100226-CD301)